S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
S&P 500   4,293.93 (+0.62%)
DOW   33,833.61 (+0.50%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)

OptimizeRx (OPRX) Stock Forecast, Price & News

$14.93
+0.02 (+0.13%)
(As of 06/8/2023 ET)
Compare
Today's Range
$14.70
$15.10
50-Day Range
$11.63
$15.63
52-Week Range
$11.59
$30.82
Volume
90,641 shs
Average Volume
209,095 shs
Market Capitalization
$255.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

OptimizeRx MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
39.9% Upside
$21.00 Price Target
Short Interest
Healthy
4.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.81) to ($0.74) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Computer And Technology Sector

166th out of 594 stocks

Business Services, Not Elsewhere Classified Industry

35th out of 90 stocks


OPRX stock logo

About OptimizeRx (NASDAQ:OPRX) Stock

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell on November 8, 1985 and is headquartered in Rochester, MI.

Receive OPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter.

OPRX Stock News Headlines

[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
SVB Securities Reaffirms Their Buy Rating on OptimizeRx (OPRX)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
Recap: OptimizeRx Q1 Earnings
OptimizeRx (OPRX) Gets a Buy from RBC Capital
OptimizeRx (OPRX) to Release Earnings on Wednesday
OptimizeRx Co. (NASDAQ:OPRX) Sees Large Drop in Short Interest
See More Headlines

OPRX Price History

OPRX Company Calendar

Last Earnings
5/10/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Business services, not elsewhere classified
Sub-Industry
N/A
Current Symbol
NASDAQ:OPRX
Employees
97
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$16.00
Forecasted Upside/Downside
+39.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$-11,440,000.00
Pretax Margin
-22.79%

Debt

Sales & Book Value

Annual Sales
$62.45 million
Book Value
$7.35 per share

Miscellaneous

Free Float
16,374,000
Market Cap
$257.12 million
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Will Febbo
    Chief Executive Officer & Director
  • Edward Stelmakh
    Chief Operations & Financial Officer
  • Todd Inman
    Chief Technology Officer
  • Marion K. Odence-Ford
    Chief Compliance Officer & General Counsel
  • Angelo Campano
    Senior Vice President & Principal-Agency Channels













OPRX Stock - Frequently Asked Questions

Should I buy or sell OptimizeRx stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptimizeRx in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OPRX shares.
View OPRX analyst ratings
or view top-rated stocks.

What is OptimizeRx's stock price forecast for 2023?

7 Wall Street research analysts have issued 1-year price targets for OptimizeRx's shares. Their OPRX share price forecasts range from $16.00 to $30.00. On average, they expect the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 40.4% from the stock's current price.
View analysts price targets for OPRX
or view top-rated stocks among Wall Street analysts.

How have OPRX shares performed in 2023?

OptimizeRx's stock was trading at $16.80 on January 1st, 2023. Since then, OPRX stock has decreased by 11.0% and is now trading at $14.96.
View the best growth stocks for 2023 here
.

Are investors shorting OptimizeRx?

OptimizeRx saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 710,500 shares, a decline of 19.7% from the April 30th total of 884,500 shares. Based on an average daily trading volume, of 250,800 shares, the days-to-cover ratio is presently 2.8 days. Approximately 4.3% of the shares of the company are sold short.
View OptimizeRx's Short Interest
.

When is OptimizeRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our OPRX earnings forecast
.

How were OptimizeRx's earnings last quarter?

OptimizeRx Co. (NASDAQ:OPRX) posted its earnings results on Wednesday, May, 10th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.02. The company earned $13 million during the quarter, compared to analyst estimates of $12.37 million. OptimizeRx had a negative net margin of 22.79% and a negative trailing twelve-month return on equity of 9.27%.

What ETFs hold OptimizeRx's stock?

ETFs with the largest weight of OptimizeRx (NASDAQ:OPRX) stock in their portfolio include Jacob Forward ETF (JFWD), Fidelity Digital Health ETF (FDHT), Global X Telemedicine & Digital Health ETF (EDOC),

What guidance has OptimizeRx issued on next quarter's earnings?

OptimizeRx updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $68.69M-, compared to the consensus revenue estimate of $68.64 million.

What other stocks do shareholders of OptimizeRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OptimizeRx investors own include InterDigital (IDCC), Bank of Hawaii (BOH), NVIDIA (NVDA), STAG Industrial (STAG), Etsy (ETSY), Marvell Technology (MRVL), Trade Desk (TTD), Verizon Communications (VZ), Advanced Micro Devices (AMD) and Amgen (AMGN).

What is OptimizeRx's stock symbol?

OptimizeRx trades on the NASDAQ under the ticker symbol "OPRX."

Who are OptimizeRx's major shareholders?

OptimizeRx's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.08%), First Light Asset Management LLC (5.90%), Blair William & Co. IL (4.93%), G2 Investment Partners Management LLC (3.13%), Wasatch Advisors LP (2.74%) and State Street Corp (2.47%). Insiders that own company stock include Douglas P Baker, Douglas P Baker, Edward Stelmakh, Ellen O'connor Vos, Gregory D Wasson, James Paul Lang, Marion Odence-Ford, Miriam J Paramore, Patrick D Spangler, Stephen L Silvestro, Stephen L Silvestro and William J Febbo.
View institutional ownership trends
.

How do I buy shares of OptimizeRx?

Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is OptimizeRx's stock price today?

One share of OPRX stock can currently be purchased for approximately $14.96.

How much money does OptimizeRx make?

OptimizeRx (NASDAQ:OPRX) has a market capitalization of $256.26 million and generates $62.45 million in revenue each year. The company earns $-11,440,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How can I contact OptimizeRx?

OptimizeRx's mailing address is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. The official website for the company is www.optimizerx.com. The company can be reached via phone at (248) 651-6568, via email at oprx@cma.team, or via fax at 248-453-5529.

This page (NASDAQ:OPRX) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -